Corbus Pharmaceuticals Holdings, Inc. (CRBP)
NASDAQ: CRBP · Real-Time Price · USD
9.25
-0.02 (-0.22%)
Aug 1, 2025, 9:42 AM - Market open

Company Description

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness.

It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells for the treatment of solid tumors; CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.

It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings.

The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings logo
CountryUnited States
Founded2009
IndustryBiotechnology
SectorHealthcare
Employees28
CEOYuval Cohen

Contact Details

Address:
500 River Ridge Drive
Norwood, Massachusetts 02062
United States
Phone617 963 0100
Websitecorbuspharma.com

Stock Details

Ticker SymbolCRBP
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001595097
CUSIP Number21833P103
ISIN NumberUS21833P3010
Employer ID46-4348039
SIC Code2834

Key Executives

NamePosition
Dr. Yuval Cohen Ph.D.Chief Executive Officer and Director
Dr. Dominic Smethurst M.A., M.D.Chief Medical Officer
Dr. Ian HodgsonChief Operating Officer
G. Scott Goeken J.D., M.S.General Counsel and Corporate Secretary
Christina BertschVice President of Human Resources

Latest SEC Filings

DateTypeTitle
Jul 29, 2025SCHEDULE 13G/AFiling
Jul 16, 2025SCHEDULE 13G/AFiling
May 19, 20258-KCurrent Report
May 6, 202510-QQuarterly Report
May 6, 20258-KCurrent Report
Apr 1, 2025ARSFiling
Apr 1, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 1, 2025DEF 14AOther definitive proxy statements
Mar 21, 20258-KCurrent Report
Mar 18, 20258-KCurrent Report